Articles From: TESSCO Technologies Schedules Second-Quarter Fiscal 2015 Earnings Release and Conference Call to Tetraphase to Present Research at ICAAC on Its Novel Chemistry Platform’s Ability to Address Antibiotic Resistance


TESSCO Technologies Incorporated (Nasdaq:TESS), Your Total Source® for the product and value chain solutions to build, use and resell wireless systems, will report financial results for its second fiscal quarter ended September 28, 2014 after the market closes on Thursday, October 23, 2014.
Sign-up for TESSCO Technologies Schedules Second-Quarter Fiscal 2015 Earnings Release and Conference Call investment picks
Tessera Technologies, Inc. (NASDAQ: TSRA) ("Tessera" or the “Company") and Micron Technology, Inc. (“Micron”) (NASDAQ: MU) announced today the execution of new, multiyear technology and patent license agreements.
Sign-up for Tessera Technologies and Micron Technology Announce Execution of New Technology and Patent License Agreements investment picks
Tessera Technologies, Inc. (NASDAQ: TSRA) (the “Company” or “we”) today announced strong financial results for the second quarter of 2014.
Sign-up for Tessera Technologies Announces Strong Second Quarter 2014 Results investment picks
Tessera Technologies, Inc. (NASDAQ:TSRA) ("Tessera" or the “Company") today announced it has named Craig Mitchell as chief technology officer for Tessera and president of Invensas Corporation, effective immediately.
Sign-up for Tessera Technologies Names Craig Mitchell as CTO and President of Invensas investment picks
Tessera Technologies, Inc. (NASDAQ:TSRA) ("Tessera" or the “Company") will announce its financial results for the third quarter ended September 30, 2014 on Thursday, October 30, 2014, following the close of the market.
Sign-up for Tessera Technologies to Report Third Quarter 2014 Results on Thursday, October 30 investment picks
CHENGDU, China , Aug.
Sign-up for Testing Runs Progress Updates for TPI's Qionglai Facility investment picks
2014/10/9
Harris Corporation’s new Falcon ® RF-330E-TR Wideband Rifleman Team Radio meets, and in many cases, exceeds the requirements for the Rifleman Radio Program, recent independent tests show.
Sign-up for Tests Show Harris Corporation Wideband Rifleman Team Radio Meets/Exceeds Program Requirements investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0968109001&sourceType=1 http://www.ccnmatthews.com/logos/20090524-tethylo2.JPG GRAND CAYMAN, CAYMAN ISLANDS --
Sign-up for Tethys Petroleum Limited: Operations and Corporate Update investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0973769001&sourceType=1 http://www.ccnmatthews.com/logos/20090524-tethylo2.JPG GRAND CAYMAN, CAYMAN ISLANDS --
Sign-up for Tethys Petroleum Limited: Shareholder Requisition of Extraordinary General Meeting investment picks
Tetra Tech, Inc. (NASDAQ: TTEK) today is providing an update on its previously announced plan to restructure the Remediation and Construction Management (RCM) segment.
Sign-up for Tetra Tech Provides Update on RCM Segment Restructuring investment picks
Tetra Tech, Inc. (NASDAQ: TTEK) today announced results for the third quarter ended June 29, 2014, the declaration of a quarterly dividend and changes to the share buyback program.
Sign-up for Tetra Tech Reports Third Quarter Results, Quarterly Dividend and Changes to Share Buyback investment picks
Tetra Tech, Inc. (NASDAQ: TTEK) announced today it has been awarded a five-year, $23 million single-award contract with the U.S. Environmental Protection Agency (EPA) to assess and reduce the human health and ecological risk from contaminated fish, sediments, and water-borne pathogens in fresh and marine waters.
Sign-up for Tetra Tech Wins $23 Million U.S. EPA Water Contract investment picks
Tetra Tech, Inc. (NASDAQ: TTEK) announced today it has been awarded a five-year, $23.6 million single-award contract with the U.S. Navy to assess and mitigate environmental impacts from expanded training grounds at the Marine Corps Air Ground Combat Center (MCAGCC) in Twentynine Palms, California.
Sign-up for Tetra Tech Wins $23.6 Million U.S. Navy Environmental Contract investment picks
Tetra Tech, Inc. (NASDAQ: TTEK) announced today it has been awarded a five-year Indefinite Delivery-Indefinite Quantity, $30 million contract with the National Institute of Standards and Technology (NIST) to provide engineering services for the NIST Center for Neutron Research (NCNR). Tetra Tech will support the NCNR by providing world-class engineering services, including conceptual design/requirements analysis, and systems design and integration services to support upgrades for scientific instrumentation, procedures, and other NCNR components.
Sign-up for Tetra Tech Wins $30 Million NIST Engineering Services Contract investment picks
Tetra Tech, Inc. (NASDAQ: TTEK) announced today it has been awarded a five-year, $76 million contract with the U.S. Environmental Protection Agency (EPA) Region 4 to provide technical and advisory services to the Superfund Technical Assessment and Response Team (START IV). Tetra Tech will provide broad scientific and technical support services under START IV to assist the EPA in protecting human health and the environment in response to man-made and natural emergencies and disasters, and at polluted sites.
Sign-up for Tetra Tech Wins $76 Million U.S. EPA Superfund Contract investment picks
Tetra Tech, Inc. (NASDAQ: TTEK) announced today it has been awarded three indefinite delivery indefinite quantity (IDIQ) contracts with the U.S. General Services Administration (GSA). The One Acquisition Solution for Integrated Services (OASIS) contracts are designed as vehicles to address all federal agencies’ needs for a full range of service requirements that integrate multiple professional service disciplines.
Sign-up for Tetra Tech Wins Three GSA OASIS Contracts investment picks
THE WOODLANDS, Texas , Aug.
Sign-up for TETRA Technologies, Inc. Announces Second Quarter 2014 Results And Revises 2014 Earnings Guidance investment picks
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced the closing of its underwritten public offering of 4,542,500 shares of common stock at an offering price of $19.00 per share.
Sign-up for Tetraphase Pharmaceuticals Announces Closing of Public Offering of Common Stock investment picks
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced initiation of patient enrollment in the pivotal portion of its IGNITE 2 Phase 3 clinical trial, a two-part trial studying the efficacy and safety of intravenous (IV) and oral formulations of eravacycline for the treatment of complicated urinary tract infections (cUTI). The company has selected the 200 mg eravacycline oral dose for the pivotal portion of the study after evaluating the positive results from the lead-in portion of the trial.
Sign-up for Tetraphase Pharmaceuticals Announces Initiation of Pivotal Portion of IGNITE 2 Phase 3 Trial of Eravacycline in cUTI investment picks
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced that positive top-line results from the lead-in portion of its IGNITE 2 clinical trial, a two-part Phase 3 clinical trial studying the efficacy and safety of intravenous (IV) and oral formulations of eravacycline for the treatment of complicated urinary tract infections (cUTI), support advancement of the trial into its pivotal portion.
Sign-up for Tetraphase Pharmaceuticals Announces Positive Oral Dosing Data from Lead-in of IGNITE 2 Phase 3 Trial of Eravacycline in cUTI Support Advancement to Pivotal Portion investment picks
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) announced today that researchers will present a poster at IDWeek 2014 showing the preclinical activity of eravacycline, a novel tetracycline in late-stage clinical development, against several Gram-negative pathogens found in New York City—a city particularly plagued by multidrug-resistant (MDR) bacteria.
Sign-up for Tetraphase Pharmaceuticals Announces Presentation of Data at IDWEEK on the Activity of Eravacycline Against Multidrug-Resistant Bacteria investment picks
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced that it intends to offer and sell up to $75,000,000 of shares of its common stock in an underwritten public offering.
Sign-up for Tetraphase Pharmaceuticals Announces Proposed Public Offering of Common Stock investment picks
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) announced today that it has completed patient enrollment in IGNITE 1, its Phase 3 clinical trial evaluating the safety and efficacy of eravacycline in the treatment of complicated intra-abdominal infections (cIAI). The Company expects to report top-line results from IGNITE 1 in early first quarter 2015.
Sign-up for Tetraphase Pharmaceuticals Completes Enrollment of IGNITE 1 Eravacycline Phase 3 Clinical Trial in Complicated Intra-abdominal Infections investment picks
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today reported financial results and key operational highlights for the second quarter ended June 30, 2014.
Sign-up for Tetraphase Pharmaceuticals Reports Second-Quarter 2014 Financial Results investment picks
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing a portfolio of potent new antibiotics designed to be effective against multidrug-resistant bacteria, today announced its participation in two upcoming investor conferences: About Tetraphase Pharmaceuticals, Inc. Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections, including those caused by many of the multidrug-resistant Gram-negative bacteria highlighted as urgent public health threats by the Centers for Disease Control and Prevention (CDC). Tetraphase's lead product candidate, eravacycline, is being developed as a broad-spectrum intravenous and oral antibiotic in the IGNITE program ( I nvestigating G
Sign-up for Tetraphase Pharmaceuticals to Participate in Upcoming Investor Conferences investment picks
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) , a clinical-stage biopharmaceutical company whose lead product candidate, eravacycline, is being developed as a broad-spectrum intravenous and oral antibiotic designed to be effective against dangerous, drug-resistant bacteria (including multidrug-resistant (MDR) Gram-negative pathogens), today announced that Guy Macdonald, Tetraphase President and Chief Executive Officer , will present at BioCentury’s 2014 NewsMakers in the Biotech Industry Conference on Friday, September 26 th at 2:30 p.m. Eastern Time.
Sign-up for Tetraphase Pharmaceuticals to Present at BioCentury’s 2014 NewsMakers in the Biotech Industry Conference investment picks
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing a portfolio of potent new antibiotics designed to be effective against multidrug-resistant bacteria, today announced that Guy Macdonald, Tetraphase President and Chief Executive Officer , will present at the annual Wedbush Life Sciences Conference on Wednesday, August 13 at 2:30 p.m. Eastern Time.
Sign-up for Tetraphase Pharmaceuticals to Present at Wedbush Life Sciences Conference investment picks
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) announced today that nine posters and one oral presentation on data related to the Company’s next-generation antibiotics portfolio – including its lead candidate eravacycline that is currently in Phase 3 clinical development for treatment of bacterial infections including multidrug-resistant (MDR) infections – will be presented at the upcoming 2014 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). The research will highlight: ICAAC 2014 occurs in Washington, DC from September 5 – 9, 2014, at the Walter E.
Sign-up for Tetraphase to Present Research at ICAAC on Its Novel Chemistry Platform’s Ability to Address Antibiotic Resistance investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: TESSCO Technologies Schedules Second-Quarter Fiscal 2015 Earnings Release and Conference Call to Tetraphase to Present Research at ICAAC on Its Novel Chemistry Platform’s Ability to Address Antibiotic Resistance
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices